•  
  •  
  •  
  •  

2026-07-22 06:57:50

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  AlkemLaboratories

Stock Report

  • Alkem Laboratories becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Alkem launches A to Z Daily, an everyday multivitamin supplement for body and mind
  • Alkem Laboratories Doubles Investment for Ujjain Greenfield Facility
  • USFDA inspection at the manufacturing facility of Enzene Biosciences Limited
  • GMP Inspection by Malta Medicines Authority at Alkem's manufacturing facility located at Daman, India
  • GMP Inspection by Ministry of Health, Armenia at Alkem's manufacturing facility located at Sikkim, India
  • Alkem launches probiotic 'DSS', the original De Simone formulation, in India for gut health management
  • Alkem Foundation and IIT Bombay announce strategic collaboration to set up advanced research centre for immunotherapeutics and regenerative medicines
  • Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer
  • Alkem launches Olesoft Trucera, an advanced ceramide-boosting moisturizing lotion for skin barrier repair
  • Alkem Medtech to acquire 100% stake of Bombay Ortho
  • US FDA Inspection at Alkem Laboratories Ltd's Bioequivalence Center located at Taloja
  • Alkem Laboratories launches generic empagliflozin and its combinations in India under the brand name 'Empanorm'
  • Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics
  • Alkem Laboratories denies claims of Pan-D, Clavam 625 batches being not-of-standard quality
  • Closure of US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Baddi, India
  • Alkem Laboratories Ltd receives Form 483 with 10 observations for Baddi facility
  • Closure of US FDA Inspection at Alkem Laboratories Ltd's API manufacturing facility located at Mandva
  • Alkem Laboratories Ltd updates on sale of S&B Pharma LLC's facility
  • Alkem Laboratories Ltd receives 3 observations from USFDA for API manufacturing facility located at Mandva
  • BIOSERGEN, ALKEM collaborate to develop anti-infective for severe fungal infections
  • Alkem Laboratories Ltd recommends final dividend of Rs. 10

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025